HC Wainwright Issues Negative Outlook for ALDX Earnings

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimate for Aldeyra Therapeutics to ($0.16), down from a previous estimate of ($0.12), while maintaining a "Buy" rating with a price target of $10.00.
• Aldeyra Therapeutics recently reported Q2 earnings of ($0.16) per share, exceeding analyst expectations of ($0.21) by $0.05.
• Institutional investors collectively hold 59.71% of Aldeyra Therapeutics' shares, with significant increases in holdings from firms like Rhumbline Advisers and Intech Investment Management in the last quarter.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2025 EPS estimates for Aldeyra Therapeutics in a report released on Monday, August 11th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will earn ($0.16) per share for the quarter, down from their prior estimate of ($0.12). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics' Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.13) EPS, FY2027 earnings at $0.43 EPS and FY2028 earnings at $0.83 EPS.

A number of other equities analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. Zacks Research raised shares of Aldeyra Therapeutics to a "hold" rating in a research report on Friday, August 8th.

Aldeyra Therapeutics Price Performance

Shares of ALDX stock traded up $0.09 on Wednesday, reaching $5.39. 912,262 shares of the company were exchanged, compared to its average volume of 1,070,304. The company has a market cap of $322.86 million, a price-to-earnings ratio of -6.34 and a beta of 0.76. The company has a 50-day moving average of $4.41 and a 200-day moving average of $4.25. Aldeyra Therapeutics has a one year low of $1.14 and a one year high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05.

Insider Buying and Selling at Aldeyra Therapeutics

In related news, insider Stephen Machatha sold 22,073 shares of the company's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $5.15, for a total value of $113,675.95. Following the sale, the insider owned 221,799 shares in the company, valued at $1,142,264.85. This represents a 9.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 9.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Captrust Financial Advisors raised its holdings in shares of Aldeyra Therapeutics by 9.1% in the 2nd quarter. Captrust Financial Advisors now owns 51,492 shares of the biotechnology company's stock worth $197,000 after acquiring an additional 4,297 shares during the last quarter. 683 Capital Management LLC raised its holdings in shares of Aldeyra Therapeutics by 126.9% in the 2nd quarter. 683 Capital Management LLC now owns 1,080,000 shares of the biotechnology company's stock worth $4,136,000 after acquiring an additional 604,000 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Aldeyra Therapeutics in the 2nd quarter worth about $101,000. AQR Capital Management LLC raised its holdings in shares of Aldeyra Therapeutics by 275.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company's stock worth $5,645,000 after acquiring an additional 1,081,257 shares during the last quarter. Finally, Caption Management LLC increased its stake in Aldeyra Therapeutics by 110.6% in the 2nd quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company's stock valued at $49,000 after buying an additional 132,358 shares during the last quarter. Institutional investors and hedge funds own 59.71% of the company's stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.